Abstract
Migraine is a frequent neurologic disorder, where different anatomical structures and it’s physiopathological mechanisms, involve activation of the trigeminovascular pathway and the onset of 5 phases. Therefore, it results of great importance, allowing to explore therapeutic options.
Strategies in management of migraine involve non pharmacological and pharmacological measures. Acute treatment should be initiated prematurely, following a personalized structure and management of pain. Preventive treatment becomes a challenge for medical practitioners, due to the use of medications that had originally been made with other purposes, some examples are beta blockers, tricyclic antidepressants and antiepileptics.Recently there are new therapies in the management of migraine such as monoclonal antibodies targeting CGRP. Medications like erenumab, fremanezumab, galcanezumab and eptinezumab have surged as options in the prevention of migraine episodes specifically in this biochemical pathway.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Jackeline Quirós Pérez, Cristian Andres Herdoiza Morales, Jorge Andres Segnini Miranda